Find a Clinical Trial

Trial Description: The purpose of this research is to determine whether a 16-week exercise program for individuals with breast cancer and have completed treatment (i.e., surgery, chemotherapy, or radiation) for breast cancer will decrease inflammation in fat tissue.

• Conditions: breast cancer, breast cancer stage i, breast cancer stage ii, breast cancer stage iii
• Phase: Not Applicable
• Trial ID: NCT04720209
• Protocol ID: 20-172

Trial Description: This randomized phase II trial studies how well afimoxifene works in reducing the risk of breast cancer in women with mammographically dense breast. Estrogen can cause the growth of breast cancer cells. Hormone therapy using afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells.

• Conditions: mammographically dense breast
• Phase: II
• Trial ID: NCT03063619
• Protocol ID: 17-745

Trial Description: The best available evidence suggests that pregnancy after breast cancer does not increase a woman's risk of developing a recurrence from her breast cancer. In particular, the most recent data suggest that this is the case also in women with a hormone receptor-positive breast cancer. There is also no indication of increased risk for delivery complications or for the newborn. The aim of the study is to investigate if temporary interruption of endocrine therapy, with the goal to permit pregnancy, is associated with a higher risk of breast cancer recurrence.The study aims also to evaluate different specific indicators related to fertility, pregnancy and breast cancer biology in young women. A psycho-oncological companion study on fertility concerns, psychological well-being and decisional conflicts will be conducted in interested Centers.

• Conditions: early breast cancer
• Phase: III
• Trial ID: NCT02308085
• Protocol ID: 15-717

Trial Description: This phase II trial studies how well FDG-PET/CT works in assessing the response of patients with breast cancer that has spread to the bones or mostly to the bones (bone-dominant metastatic breast cancer). Diagnostic procedures, such as FDG-PET/CT, may work better in measuring breast cancer activity before and after treatment compared to other standard imaging tests.

• Conditions: anatomic stage iv breast cancer ajcc v8, hormone receptor positive breast carcinoma, metastatic breast carcinoma, prognostic stage iv breast cancer ajcc v8
• Phase: II
• Trial ID: NCT04316117
• Protocol ID: 20-430

Trial Description: This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed. This study aims to test whether overweight or obese women who take part in a weight loss program after being diagnosed with breast cancer have a lower rate of cancer recurrence as compared to women who do not take part in the weight loss program. This study will help to show whether weight loss programs should be a part of breast cancer treatment.

• Conditions: breast carcinoma
• Phase: III
• Trial ID: NCT02750826
• Protocol ID: 16-716

Trial Description: This research study is evaluating how well Breast Cancer responds to preoperative treatment with Endocrine treatment in combination with a drug called Palbociclib or Endocrine treatment alone as possible treatments for Hormone Receptor Positive Breast Cancer.

• Conditions: breast cancer
• Phase: II
• Trial ID: NCT02764541
• Protocol ID: 16-052

Trial Description: A Phase 2, clinical study in advanced, metastatic breast cancer that will evaluate CX-2009 monotherapy in both Hormone Receptor(HR) positive/HER2 negative breast cancer and in TNBC, and evaluate CX-2009+CX-072 in TNBC

• Conditions: breast cancer, breast neoplasms, breast neoplasms hormone receptor positive/her2 negative, breast neoplasms triple-negative, neoplasms
• Phase: II
• Trial ID: NCT04596150
• Protocol ID: 21-130

Trial Description: This research study is studying an investigational drug as a possible treatment for breast cancer that is positive for the protein Human Epidermal Growth Factor Receptor 2, also known as HER2-positive breast cancer. The drug involved in this study is: -ado-trastuzumab emtansine (T-DM1)

• Conditions: breast cancer
• Phase: II
• Trial ID: NCT03587740
• Protocol ID: 18-124

Trial Description: This Feasibility study is trying to determine: - If Lymphoscintigraphy (imaging of the lymphatic drainage patterns) is effective in demonstrating the drainage to the sentinel lymph nodes in patients with inflammatory breast cancer. - The likelihood of identifying the sentinel lymph nodes in the operating room, using both blue dye and the radioactive substance used for lymphoscintigraphy. - The incidence of lymphedema (arm swelling which occurs after lymph node surgery) in women with inflammatory breast cancer - Outcomes for women with inflammatory breast cancer, whether or not the sentinel lymph nodes can be identified.

• Conditions: breast cancer, inflammatory breast cancer, sentinel lymph node
• Phase: Feasibility / Pilot
• Trial ID: NCT04636710
• Protocol ID: 20-151

Trial Description: This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells or reducing the amount of estrogen made by the body. Giving alisertib with or without fulvestrant may be better in treating patients with breast cancer.

• Conditions: estrogen receptor status, her2/neu negative, invasive breast carcinoma, postmenopausal, stage iii breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer
• Phase: II
• Trial ID: NCT02860000
• Protocol ID: 18-343

Trial Description: This research study is a way of gaining new knowledge about whether patients can omit radiation treatment after undergoing a lumpectomy, also known as "breast conserving surgery". In this trial, we are attempting to identify which patients may not need radiation.

• Conditions: breast cancer radiation
• Phase: II
• Trial ID: NCT02653755
• Protocol ID: 15-255

Trial Description: This clinical trial compares a web-based patient-reported symptom monitoring and self management portal, Young, Empowered & Strong (YES), to standard therapy in managing symptoms in adolescent and young adults breast cancer survivors. YES is a web-based portal (website) to help monitor issues or symptoms women with breast cancer may experience. YES portal may improve the quality of life of young breast cancer survivors. YES portal may help manage symptoms and provide useful information/resources.

• Conditions: anatomic stage 0 breast cancer ajcc v8, anatomic stage i breast cancer ajcc v8, anatomic stage ia breast cancer ajcc v8, anatomic stage ib breast cancer ajcc v8, anatomic stage ii breast cancer ajcc v8, anatomic stage iia breast cancer ajcc v8, anatomic stage iib breast cancer ajcc v8, anatomic stage iii breast cancer ajcc v8, anatomic stage iiia breast cancer ajcc v8, anatomic stage iiib breast cancer ajcc v8, anatomic stage iiic breast cancer ajcc v8, prognostic stage 0 breast cancer ajcc v8, prognostic stage i breast cancer ajcc v8, prognostic stage ia breast cancer ajcc v8, prognostic stage ib breast cancer ajcc v8, prognostic stage ii breast cancer ajcc v8, prognostic stage iia breast cancer ajcc v8, prognostic stage iib breast cancer ajcc v8, prognostic stage iii breast cancer ajcc v8, prognostic stage iiia breast cancer ajcc v8, prognostic stage iiib breast cancer ajcc v8, prognostic stage iiic breast cancer ajcc v8
• Phase: III
• Trial ID: NCT04906200
• Protocol ID: 21-167

Trial Description: This research study is studying the usefulness of magnetic resonance imaging (MRI) to screen for brain metastases (spread of the breast cancer to the brain).

• Conditions: breast cancer, her2-positive breast cancer, hormone receptor positive malignant neoplasm of breast, inflammatory breast cancer, metastatic breast cancer, triple negative breast cancer
• Phase: II
• Trial ID: NCT04030507
• Protocol ID: 19-066

Trial Description: This research is being conducted to develop consensus on surveillance mammography and follow-up for breast cancer survivors who are age ≥75.

• Conditions: breast cancer
• Phase: Not Applicable
• Trial ID: NCT03865654
• Protocol ID: 19-001

Trial Description: This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patient's immune system. This trial includes a two week induction or lead-in of medications that can stimulate the immune system. It is our hope

• Conditions: invasive breast carcinoma, recurrent breast carcinoma, stage iii breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer, triple-negative breast carcinoma, unresectable breast carcinoma
• Phase: II
• Trial ID: NCT03971409
• Protocol ID: 22-468

Trial Description: This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.

• Conditions: anatomic stage ia breast cancer ajcc v8, anatomic stage ii breast cancer ajcc v8, anatomic stage iia breast cancer ajcc v8, anatomic stage iib breast cancer ajcc v8, anatomic stage iii breast cancer ajcc v8, anatomic stage iiia breast cancer ajcc v8, anatomic stage iiib breast cancer ajcc v8, anatomic stage iiic breast cancer ajcc v8, her2 positive breast carcinoma, invasive breast carcinoma, multifocal breast carcinoma, prognostic stage i breast cancer ajcc v8, prognostic stage ia breast cancer ajcc v8, prognostic stage ib breast cancer ajcc v8, prognostic stage ii breast cancer ajcc v8, prognostic stage iia breast cancer ajcc v8, prognostic stage iib breast cancer ajcc v8, prognostic stage iii breast cancer ajcc v8, prognostic stage iiia breast cancer ajcc v8, prognostic stage iiib breast cancer ajcc v8, prognostic stage iiic breast cancer ajcc v8, synchronous bilateral breast carcinoma
• Phase: III
• Trial ID: NCT04457596
• Protocol ID: 21-560

Trial Description: The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.

• Conditions: advanced breast cancer, breast cancer, endometrial cancer, metastatic breast cancer
• Phase: I
• Trial ID: NCT04188548
• Protocol ID: 20-118

Trial Description: This randomized phase III trial studies how well mindfulness meditation or survivorship education work in improving behavioral symptoms in younger stage 0-III breast cancer survivors. Behavioral interventions, such as mindfulness meditation, use techniques to help patients change the way they react to environmental triggers that may cause a negative reaction. Survivorship education after treatment may reduce stress and improve the well-being and quality of life of patients with breast cancer. Mindfulness meditation or survivorship education may help improve the health behaviors of younger breast cancer survivors.

• Conditions: cancer survivor, early-stage breast carcinoma, stage 0 breast cancer, stage ia breast cancer, stage ib breast cancer, stage iia breast cancer, stage iib breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer
• Phase: Not Applicable
• Trial ID: NCT03025139
• Protocol ID: 16-569

Trial Description: This study is designed to determine the impact of a novel genetic counseling method on surgical decisions in individuals with newly diagnosed breast cancer This research study involves an expedited and surgery-specific form of genetic counseling. The names of the study methods involved in this trial are/is: - Quantitative genetic counseling (discussion is guided by tables and graphs) - Standard genetic counseling

• Conditions: breast cancer, genetic testing, in situ breast cancer, invasive breast cancer
• Phase: Feasibility / Pilot
• Trial ID: NCT04245176
• Protocol ID: 19-509

Trial Description: The proposed study is a randomized trial evaluating the impact of a dietary and physical activity guidelines intervention vs. usual care on adherence to breast cancer treatments, body composition, and changes in biomarkers in 172 women newly diagnosed with breast cancer scheduled to receive neoadjuvant or adjuvant chemotherapy.

• Conditions: breast neoplasms
• Phase: Not Applicable
• Trial ID: NCT03314688
• Protocol ID: 19-624

Trial Description: This research study involves the use of a common breast imaging modality (magnetic resonance imaging, 'MRI') and is investigating its role in evaluating surgical decision making for breast cancer when it is performed with the patient in a new position (lying on one's back) as opposed to in the standard position (lying on one's stomach).

• Conditions: breast cancer
• Phase: Not Applicable
• Trial ID: NCT02956473
• Protocol ID: 16-277

Trial Description: This randomized phase III trial studies lymph node dissection and radiation therapy to see how well it works compared to radiation therapy alone in treating patients with breast cancer previously treated with chemotherapy and surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x rays or protons to kill tumor cells. It is not yet known if radiation therapy works better alone or with lymph node dissection in treating patients with breast cancer previously treated with chemotherapy and surgery.

• Conditions: stage ii breast cancer, stage iiia breast cancer
• Phase: III
• Trial ID: NCT01901094
• Protocol ID: 14-316

Trial Description: This randomized phase III trial studies the best individual therapy for women who have node-negative, estrogen-receptor positive breast cancer by using a special test (Oncotype DX), and whether hormone therapy alone or hormone therapy together with combination chemotherapy is better for women who have an Oncotype DX recurrence score of 11-25. Estrogen can cause the growth of breast cancer cells. Hormone therapy may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes. Drugs used in chemotherapy work

• Conditions: breast adenocarcinoma, hormone receptor positive, stage ia breast cancer ajcc v7, stage ib breast cancer ajcc v7, stage iia breast cancer ajcc v6 and v7, stage iib breast cancer ajcc v6 and v7, stage iiib breast cancer ajcc v7
• Phase: III
• Trial ID: NCT00310180
• Protocol ID: 06-163

Trial Description: This research is being done to assess whether an exercise intervention with protein intake support vs a health education and support program will make it easier for women age 65 or older who are receiving chemotherapy for breast cancer to receive all of their planned chemotherapy according to schedule and at the planned dose.

• Conditions: breast cancer, breast cancer female, stage i breast cancer, stage ii breast cancer, stage iii breast cancer
• Phase: II
• Trial ID: NCT05535192
• Protocol ID: 22-250

Trial Description: This study is being done to see if anti-HER2 treatment be safely stopped in patients with HER2-positive metastatic breast cancer (MBC) that have had exceptional response to treatment. Exceptional response" is considered as cancer progression being controlled for three years or more since starting anti-HER2 treatment.

• Conditions: breast cancer, her2-positive breast cancer, metastatic breast cancer
• Phase: II
• Trial ID: NCT05721248
• Protocol ID: 22-655

Trial Description: This research study is for patients with metastatic breast cancer. - Metastatic means that the cancer has spread beyond the breast. In addition, through genetic testing of the blood or tumor, an altered gene has been found that suggests the tumor may not be able to repair its genetic material (DNA) when it becomes damaged. - This aspect of the cancer may cause it to be more sensitive - that is, more effectively killed by certain types of drugs such as the study agent being evaluated in this trial, Olaparib. - Olaparib is a type of drug known as a PARP inhibitor. Some types

• Conditions: atm gene mutation, brip1 gene mutation, chek2 gene mutation, invasive breast cancer, metastatic breast cancer, nbn gene mutation, palb2 gene mutation, rad51 gene mutation, somatic mutation breast cancer (brca1), somatic mutation breast cancer (brca2)
• Phase: II
• Trial ID: NCT03344965
• Protocol ID: 17-428

Trial Description: This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab govitecan, trastuzumab deruxtecan, or eribulin. The name of the study intervention involved in this study is: - Paxman Scalp Cooling System

• Conditions: chemotherapy-induced alopecia, metastatic breast cancer
• Phase: II
• Trial ID: NCT04986579
• Protocol ID: 21-169

Trial Description: The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain. Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2). In this research study, the investigators are looking to see how well neratinib works to decrease the size of or stabilize breast cancer that has spread to the brain. The investigators are also looking at how previous treatments have affected your thinking (or cognition) and how much neratinib reaches the central nervous system.

• Conditions: breast cancer
• Phase: II
• Trial ID: NCT01494662
• Protocol ID: 11-344

Trial Description: This research study involves Niraparib as a possible treatment for triple negative breast cancer.

• Conditions: residual disease, triple negative breast cancer
• Phase: I
• Trial ID: NCT03945721
• Protocol ID: 19-055

Trial Description: This research is evaluating the impact of a 12-week prolonged nightly fasting (POF) and exercise intervention on metabolic markers and patient reported outcomes in women with metastatic breast cancer (MBC) initiating endocrine therapy in combination with palbociclib or alpelisib.

• Conditions: breast cancer, metastatic breast cancer
• Phase: Feasibility / Pilot
• Trial ID: NCT04708860
• Protocol ID: 20-503

Trial Description: This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.

• Conditions: breast cancer, metastatic breast cancer
• Phase: I/II
• Trial ID: NCT05563220
• Protocol ID: 23-216

Trial Description: This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer

• Conditions: stage ib breast cancer, stage ii breast cancer
• Phase: III
• Trial ID: NCT01872975
• Protocol ID: 13-504

Trial Description: This is a Phase 1b open-label, 2-part study in 2 treatment groups. The 2 treatment groups are as follows: Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation

• Conditions: advanced breast cancer, her2-negative breast cancer, hr-positive breast cancer, metastatic breast cancer
• Phase: I
• Trial ID: NCT05508906
• Protocol ID: 23-378

Trial Description: This research study is evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer. The names of the study interventions involved in this study are: - Sacituzumab govitecan (IMMU-132) - Pembrolizumab (Keytruda®; MK-3475)

• Conditions: her2-negative breast cancer, hr-positive breast cancer, invasive breast cancer, metastatic breast cancer
• Phase: II
• Trial ID: NCT04448886
• Protocol ID: 20-153

Trial Description: The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs. Drugs and Combinations used: - Paclitaxel, Pertzumab and Margetuximab (Margenza) - Paclitaxel, Pertzumab and Trastuzumab (Herceptin)

• Conditions: breast cancer, her2-positive breast cancer, stage ii breast cancer, stage iii breast cancer
• Phase: II
• Trial ID: NCT04425018
• Protocol ID: 20-068

Trial Description: The purpose of this research study is to evaluate a decision aid to help women aged 70 and older decide on treatment for their breast cancer.

• Conditions: breast cancer, estrogen receptor positive breast cancer, human epidermal growth factor 2 negative carcinoma of breast, node-negative breast cancer
• Phase: Not Applicable
• Trial ID: NCT02823262
• Protocol ID: 16-117

Trial Description: This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: - Sacituzumab govitecan (SG) - Pembrolizumab (combination therapy with SG)

• Conditions: er-negative breast cancer, her2-negative breast cancer, invasive breast cancer, pr-negative breast cancer, triple negative breast cancer
• Phase: II
• Trial ID: NCT04230109
• Protocol ID: 19-578

Trial Description: This research study is studying a combination of drugs as a possible treatment for breast cancer with a BRCA mutation. The interventions involved in this study are: - Sapacitabine (CYC682) - Olaparib (Lynparza™)

• Conditions: breast cancer
• Phase: I/II
• Trial ID: NCT03641755
• Protocol ID: 18-223

Trial Description: Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast cancer, recurrent platinum sensitive ovarian cancer, urothelial cancer (UC), and castration resistant prostate cancer (CRPC).

• Conditions: avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors
• Phase: I/II
• Trial ID: NCT03330405
• Protocol ID: 17-687

Trial Description: This research study is studying a drug called Abemaciclib as a possible treatment for have metastatic triple-negative type of breast cancer.

• Conditions: breast cancer
• Phase: II
• Trial ID: NCT03130439
• Protocol ID: 17-024

Trial Description: This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer. The study drugs involved in this study are: - A combination of trastuzumab and pertuzumab given as an injection under the skin (PHESGO) - Hormonal (endocrine) Treatment

• Conditions: breast cancer, her2-positive breast cancer, hormone receptor positive breast cancer, invasive carcinoma of the breast, micrometastasis breast cancer, node negative breast cancer
• Phase: II
• Trial ID: NCT04569747
• Protocol ID: 20-347

Trial Description: This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: - Trastuzumab-emtansine (T-DM1, Kadcyla) - Trastuzumab SC (Herceptin Hylecta) - Paclitaxel

• Conditions: breast cancer, her2-positive breast cancer
• Phase: II
• Trial ID: NCT04893109
• Protocol ID: 21-159

Trial Description: This research study is a way of gaining new knowledge about the combination of Taselisib with other drugs in the treatment of metastatic breast cancer. Taselisib is an investigational drug which works by blocking a protein called PI3K (phosphoinositide 3-kinase) that helps cancer cells grow. This drug has been used in laboratory experiments and information from these studies suggests that this drug may help to prevent or slow the growth of cancer cells. The main purpose of this study is to find the appropriate dose of Taselisib to be used with other drugs in further clinical studies. This is an open-label, 3+3 dose-escalation phase Ib study to identify the Maximum Tolerated Dose(s) (MTD) and to identify the recommended phase 2 dose (RP2D) of Taselisib. This study will be conducted in 4 separate arms. (A-D).

• Conditions: metastatic breast cancer, recurrent breast cancer
• Phase: I
• Trial ID: NCT02390427
• Protocol ID: 15-024

Trial Description: This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide, or ongoing endocrine therapy) for breast cancer that has spread to other parts of the body.

• Conditions: breast neoplasms
• Phase: I
• Trial ID: NCT02057133
• Protocol ID: 14-070

Trial Description: The aim of this study is to determine the impact of the voice-activated smart speaker CBT-I components on insomnia symptoms among breast cancer survivors using a randomized clinical trial.

• Conditions: breast cancer survivor, insomnia
• Phase: I
• Trial ID: NCT05233800
• Protocol ID: 22-022

Trial Description: This study will examine the safety and tolerability of ladiratuzumab vedotin (LV) in patients with metastatic breast cancer. LV will be given alone or in combination with trastuzumab.

• Conditions: her2 mutations breast neoplasms, her2 positive breast neoplasms, hormone receptor positive breast neoplasms, triple negative breast neoplasms
• Phase: I
• Trial ID: NCT01969643
• Protocol ID: 14-306

Trial Description: This research study is evaluating acupuncture, a medical therapy in which hair-thin, stainless steel needles are shallowly inserted into specific points to help the body's natural healing process, as a possible treatment to reduce hot flashes

• Conditions: breast cancer
• Phase: Not Applicable
• Trial ID: NCT03783546
• Protocol ID: 18-371

Trial Description: The TRIP Project aims to overcome barriers to widespread implementation and dissemination of evidence-based practices that will improve the delivery of guideline-concordant care to vulnerable women with breast cancer. To accomplish this goal the study team will create (a) regional patient registries; (b) systematic screening for social barriers to care with a personalized referral plan; and (c) patient navigation services that integrate into one model of care to improve the quality and effectiveness of care delivery, for minority and/or low-income women with breast cancer in Boston.

• Conditions: cancer breast
• Phase: Not Applicable
• Trial ID: NCT03514433
• Protocol ID: 20-616

Trial Description: This phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. A germline mutation is an inherited gene change which, in the BRCA1 gene, is associated with an increased risk of breast and other cancers. Denosumab is a monoclonal antibody that is used to treat bone loss in order to reduce the risk of bone fractures in healthy people, and to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women carrying a BRCA1 germline mutation.

• Conditions: brca1 mutation, breast cancer, breast carcinoma, breast diseases, breast neoplasms, neoplasms
• Phase: III
• Trial ID: NCT04711109
• Protocol ID: 22-212

Trial Description: The purpose of this study is to investigate the use of intra-operative Magnetic Resonance Imaging (MRI) and Mass Spectrometry (MS) during breast conserving surgery, and to determine if these tests are capable of accurately predicting the presence or absence of breast tumor in surgical specimens at the margins.

• Conditions: breast cancer stage i, breast cancer stage ii, early stage breast cancer
• Phase: II
• Trial ID: NCT02335671
• Protocol ID: 14-476